Wednesday, 29 July 2015

Atherosclerosis - Pipeline Review, H1 2015

Atherosclerosis - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Atherosclerosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Atherosclerosis - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Atherosclerosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Atherosclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atherosclerosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Ache Laboratorios Farmaceuticos advanceCor GmbH AFFiRiS AG Arisaph Pharmaceuticals, Inc. Artery Therapeutics, Inc. AstraZeneca Plc Athera Biotechnologies AB AtheroNova Inc. AuraSense Therapeutics, LLC Bayer AG Bridge Bioresearch Plc Campus Technologies Freiburg G Cardax Pharmaceuticals, Inc. ChemoCentryx, Inc. CohBar Inc. DoNatur GmbH Dr. Reddy's Laboratories Limited Dybly AG Eli Lilly and Company F. Hoffmann-La Roche Ltd. GenKyoTex S.A. Gilead Sciences, Inc. Isis Pharmaceuticals, Inc. Jenrin Discovery, Inc. Johnson & Johnson KineMed, Inc. Kowa Company, Ltd. Lead Discovery Center GmbH MedImmune, LLC Merck & Co., Inc. MI.TO. Technology S.r.L. Novartis AG Omeros Corporation OPKO Health, Inc. Otsuka Holdings Co., Ltd. Provid Pharmaceuticals, Inc. Resverlogix Corp. The Medicines Company Therapix Biosciences Ltd Vascular Biogenics Ltd. Vericel Corporation Vitae Pharmaceuticals, Inc.

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Bladder Cancer - Pipeline Review, H1 2015

Bladder Cancer - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Bladder Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit Bladder Cancer - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bladder Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bladder Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bladder Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Advaxis, Inc. Alligator Bioscience AB Alnylam Pharmaceuticals, Inc. Altor BioScience Corporation Amgen Inc. AndroScience Corporation APIM Therapeutics AS Arno Therapeutics, Inc. Ascenta Therapeutics, Inc. Astellas Pharma Inc. AstraZeneca Plc AuraSense Therapeutics, LLC AVEO Pharmaceuticals, Inc. AvidBiotics Corp. Bavarian Nordic A/S Bayer AG BioCancell Ltd Bioncotech Therapeutics S.L. Biotest AG cCAM Biotherapeutics Ltd. Celgene Corporation Cold Genesys, Inc. Daiichi Sankyo Company, Limited Dompe Farmaceutici S.p.A. DormaTarg, Inc. Eisai Co., Ltd. Eli Lilly and Company EntreChem, S.L. Esperance Pharmaceuticals, Inc. Evotec AG F. Hoffmann-La Roche Ltd. Gene Signal International SA Genmab A/S GlaxoSmithKline Plc Heat Biologics, Inc. Hutchison MediPharma Limited Idera Pharmaceuticals, Inc. Immunomedics, Inc. Immupharma Plc ImmuRx, Inc. Incyte Corporation Lipella Pharmaceuticals, Inc. MacroGenics, Inc. Marina Biotech, Inc. MedImmune, LLC Merck & Co., Inc. Millennium Pharmaceuticals, Inc. Mirati Therapeutics Inc. NuCana BioMed Limited Omeros Corporation Oncogenex Pharmaceuticals, Inc. Oncolytics Biotech Inc. Oncopeptides AB Ono Pharmaceutical Co., Ltd. Optimum Therapeutics, LLC Panacela Labs, Inc. Pfizer Inc. Pharma Mar, S.A. Polaris Pharmaceuticals, Inc. PsiOxus Therapeutics Limited Qu Biologics Inc. Quest PharmaTech Inc. Samyang Holdings Corporation Sanofi SentoClone International AB Serometrix, LLC Shionogi & Co., Ltd. Spectrum Pharmaceuticals, Inc. Stemline Therapeutics, Inc. Synta Pharmaceuticals Corp. TARIS BioMedical, Inc. Telesta Therapeutics Inc. Telormedix SA Theravectys S.A. TheRyte Limited Tolero Pharmaceuticals, Inc. Transgene SA Vakzine Projekt Management GmbH Viralytics Ltd. Viventia Biotechnologies Inc.

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned
AbbVie Inc. Affimed Therapeutics AG Amgen Inc. Aprogen, Inc. Arrien Pharmaceuticals, LLC Astellas Pharma Inc. AstraZeneca Plc Aurigene Discovery Technologies Limited Bayer AG BIND Therapeutics, Inc. Biocon Limited Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cell>Point, L.L.C. Cellular Biomedicine Group, Inc. Constellation Pharmaceuticals, Inc. CTI BioPharma Corp. CureTech Ltd. Curis, Inc. Eisai Co., Ltd. EpiZyme, Inc. Erytech Pharma SA F. Hoffmann-La Roche Ltd. Genentech, Inc. Gilead Sciences, Inc. GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. ImmunoGen, Inc. Immunomedics, Inc. Immunovaccine, Inc. Incyte Corporation Infinity Pharmaceuticals, Inc. Johnson & Johnson Karus Therapeutics Limited Karyopharm Therapeutics, Inc. Kite Pharma, Inc. Mabion SA MedImmune, LLC Merck & Co., Inc. Millennium Pharmaceuticals, Inc. Mirati Therapeutics Inc. Mirna Therapeutics, Inc. Molplex Ltd. MorphoSys AG Nimbus Therapeutics, LLC Nordic Nanovector AS Novartis AG Ono Pharmaceutical Co., Ltd. Onyx Pharmaceuticals, Inc. Pfizer Inc. Pharmacyclics, Inc. Philogen S.p.A. Portola Pharmaceuticals, Inc. Priaxon AG ProNAi Therapeutics, Inc. RedHill Biopharma Ltd. Redx Pharma Ltd Respiratorius AB Rhizen Pharmaceuticals SA Sandoz International GmbH Seattle Genetics, Inc. Taiho Pharmaceutical Co., Ltd. TG Therapeutics, Inc.

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Tuesday, 28 July 2015

Myelodysplastic Syndrome - Pipeline Review, H1 2015

Myelodysplastic Syndrome - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Myelodysplastic Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit Myelodysplastic Syndrome - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

4SC AG AbbVie Inc. Acceleron Pharma, Inc. Actinium Pharmaceuticals, Inc. Advancell Agios Pharmaceuticals, Inc. Altor BioScience Corporation Amgen Inc. Apogenix GmbH Aptose Biosciences Inc. Array BioPharma Inc. Astex Pharmaceuticals, Inc. Bio-Path Holdings, Inc. BioLineRx, Ltd. Boehringer Ingelheim GmbH Boryung Pharmaceutical Co., Ltd. Boston Biomedical, Inc. Bristol-Myers Squibb Company Celator Pharmaceuticals, Inc. Celgene Corporation Celldex Therapeutics, Inc. Cellerant Therapeutics, Inc. Celyad Clevexel Pharma SAS Concert Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc. Cornerstone Pharmaceuticals, Inc. CTI BioPharma Corp. Cyclacel Pharmaceuticals, Inc. Daiichi Sankyo Company, Limited Eisai Co., Ltd. Eleos Inc. Eli Lilly and Company EpiZyme, Inc. F. Hoffmann-La Roche Ltd. Fujifilm Corporation Gamida Cell Ltd. GlaxoSmithKline Plc Incyte Corporation Juno Therapeutics Inc. JW Pharmaceutical Corporation Kainos Medicine, Inc. KaloBios Pharmaceuticals, Inc. Karyopharm Therapeutics, Inc. Kiadis Pharma B.V. Kyowa Hakko Kirin Co., Ltd. Les Laboratoires Servier SAS Lixte Biotechnology Holdings, Inc. medac GmbH MedImmune, LLC MEI Pharma, Inc. Merck & Co., Inc. Merus B.V. Millennium Pharmaceuticals, Inc. Mirati Therapeutics Inc. Mirna Therapeutics, Inc. Novartis AG Onconova Therapeutics, Inc. Opsona Therapeutics Ltd. OXiGENE, Inc. Pfizer Inc. Pharma Mar, S.A. Rich Pharmaceuticals, Inc. Stemline Therapeutics, Inc. Sumitomo Dainippon Pharma Co., Ltd. Sunesis Pharmaceuticals, Inc. Syndax Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Limited Threshold Pharmaceuticals, Inc. Tragara Pharmaceuticals, Inc.

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Small-Cell Lung Cancer - Pipeline Review, H1 2015

Small-Cell Lung Cancer - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Small-Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team experts. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Small-Cell Lung Cancer - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc. Alchemia Limited Amgen Inc. Aposense Ltd. Array BioPharma Inc. Astellas Pharma Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. Bayer AG BIND Therapeutics, Inc. Blend Therapeutics, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Cantex Pharmaceuticals, Inc. Celator Pharmaceuticals, Inc. CellAct Pharma GmbH Cerulean Pharma, Inc. Cornerstone Pharmaceuticals, Inc. Critical Outcome Technologies Inc. CytRx Corporation Eisai Co., Ltd. Eli Lilly and Company Exelixis, Inc. F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Hutchison MediPharma Limited ImmunoCellular Therapeutics, Ltd. Immunomedics, Inc. Inbiopro Solutions Pvt. Ltd. Johnson & Johnson Karyopharm Therapeutics, Inc. Kolltan Pharmaceuticals, Inc. Kyowa Hakko Kirin Co., Ltd. Lindis Biotech GmbH MabVax Therapeutics Holdings, Inc. MedImmune, LLC MEI Pharma, Inc. Merck & Co., Inc. Mersana Therapeutics, Inc. Millennium Pharmaceuticals, Inc. Mirna Therapeutics, Inc. MolMed S.p.A. Mologen AG Nektar Therapeutics Neotropix, Inc. Nippon Kayaku Co., Ltd. Novartis AG Omnitura Therapeutics Inc. OncoMed Pharmaceuticals, Inc. Ono Pharmaceutical Co., Ltd. Onxeo SA Onyx Pharmaceuticals, Inc. Oxford BioTherapeutics Ltd Pfizer Inc. Polaris Pharmaceuticals, Inc. Rexahn Pharmaceuticals, Inc. Spectrum Pharmaceuticals, Inc. Sumitomo Dainippon Pharma Co., Ltd. Synta Pharmaceuticals Corp. Tesaro, Inc. Vertex Pharmaceuticals Incorporated Zensun (Shanghai) Sci & Tech Co., Ltd. ZIOPHARM Oncology, Inc. all-Cell Lung Cancer - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Systemic Lupus Erythematosus - Pipeline Review, H1 2015

Systemic Lupus Erythematosus - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Systemic Lupus Erythematosus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To view the table of contents and know more details, please visit Systemic Lupus Erythematosus - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Lupus Erythematosus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

4SC AG AbbVie Inc. Ablynx NV Actelion Ltd AiCuris GmbH & Co. KG Amgen Inc. Anthera Pharmaceuticals‚ Inc. Argos Therapeutics, Inc. Biogen, Inc. Biotest AG Bristol-Myers Squibb Company Celgene Corporation Cellular Biomedicine Group, Inc. Eisai Co., Ltd. F. Hoffmann-La Roche Ltd. Genosco Genovax S.r.l. GlaxoSmithKline Plc Hansa Medical AB ImmuNext, Inc. Immunomedics, Inc. Immupharma Plc Invion Limited Johnson & Johnson Kadmon Corporation, LLC Kineta, Inc. Kymab Limited Lead Discovery Center GmbH MacroGenics, Inc. MedAnnex Ltd MedImmune, LLC Medsenic Merck KGaA Mitsubishi Tanabe Pharma Corporation National Pharmaceutical Corp. Neovacs SA Nippon Chemiphar Co., Ltd. Padlock Therapeutics, Inc. Pfizer Inc. Plexxikon Inc. RedHill Biopharma Ltd. Redx Pharma Ltd Resolve Therapeutics, LLC Sanofi Sarepta Therapeutics, Inc. SATT Conectus Alsace SAS SBI Biotech Co., Ltd. Seattle Genetics, Inc. Takeda Pharmaceutical Company Limited Therapix Biosciences Ltd UCB S.A. Xencor, Inc. XTL Biopharmaceuticals Ltd.

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###

Ischemia Reperfusion Injury - Pipeline Review, H1 2015

Ischemia Reperfusion Injury - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Ischemia Reperfusion Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

To access full report with TOC, please visit Ischemia Reperfusion Injury - Pipeline Review, H1 2015.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ischemia Reperfusion Injury and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ischemia Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ischemia Reperfusion Injury pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ischemia Reperfusion Injury
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Adienne Pharma & Biotech Alligator Bioscience AB Antipodean Pharmaceuticals, Inc. BioLineRx, Ltd. Biomedica Management Corporation Bolder Biotechnology, Inc. Catalyst Biosciences, Inc. Curatis Pharma GmbH Gilead Sciences, Inc. Ischemix LG Life Sciences, Ltd. Lotus Pharmaceutical Co., Ltd. Mercury Pharmaceuticals, Inc. Omeros Corporation Opsona Therapeutics Ltd. Peptinnovate Limited Pharming Group N.V. PledPharma AB Prolong Pharmaceuticals Proteo, Inc. Prothix BV Trophos SA Zealand Pharma A/S Zyrnat Biotherapeutics SL

Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###